TY - JOUR
T1 - Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
AU - Silverberg, Jonathan I.
AU - Simpson, Eric L.
AU - Boguniewicz, Mark
AU - De Bruin-Weller, Marjolein S.
AU - Foley, Peter
AU - Kataoka, Yoko
AU - Bagousse, Gaëlle Bégo Le
AU - Chen, Zhen
AU - Shumel, Brad
AU - Chao, Jingdong
AU - Rossi, Ana B.
N1 - Publisher Copyright:
© 2021, Medical Journals/Acta D-V. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Post-hoc analyses of a 1-year, randomized, double-blinded, placebo-controlled trial (NCT02260986) of dupilumab with concomitant topical corticosteroids in 421 adults with mo-derate-to-severe atopic dermatitis (of whom 315/106 received placebo/dupilumab (of whom 315 received placebo and 106 received dupilumab) was performed to assess the proportion of responders to dupilumab through a multidimensional composite endpoint. At 6-months, 80.2% of dupilumab-treated vs 40.0% placebo patients (p < 0.0001) achieved improvement in signs (Eczema Area and Severity Index ≤ 7), symptoms (worst itch score ≤ 4), or quality of life (Dermatology Life Quality Index ≤5), representative of minimal/clear atopic dermatitis. All 3 endpoints, in-dicative of no/minimal atopic dermatitis, were achieved by 44.3% of dupilumab-treated vs 10.2% placebo patients (p < 0.0001) and sustained through 1 year. Dupilumab treatment provided sustained clinically meaningful improvement in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis.
AB - Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Post-hoc analyses of a 1-year, randomized, double-blinded, placebo-controlled trial (NCT02260986) of dupilumab with concomitant topical corticosteroids in 421 adults with mo-derate-to-severe atopic dermatitis (of whom 315/106 received placebo/dupilumab (of whom 315 received placebo and 106 received dupilumab) was performed to assess the proportion of responders to dupilumab through a multidimensional composite endpoint. At 6-months, 80.2% of dupilumab-treated vs 40.0% placebo patients (p < 0.0001) achieved improvement in signs (Eczema Area and Severity Index ≤ 7), symptoms (worst itch score ≤ 4), or quality of life (Dermatology Life Quality Index ≤5), representative of minimal/clear atopic dermatitis. All 3 endpoints, in-dicative of no/minimal atopic dermatitis, were achieved by 44.3% of dupilumab-treated vs 10.2% placebo patients (p < 0.0001) and sustained through 1 year. Dupilumab treatment provided sustained clinically meaningful improvement in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis.
KW - Dermatology Life Quality Index
KW - Eczema Area and Severity Index
KW - atopic dermatitis
KW - pruritus
KW - responder
KW - treat-to-target
UR - http://www.scopus.com/inward/record.url?scp=85121955765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121955765&partnerID=8YFLogxK
U2 - 10.2340/actadv.v101.307
DO - 10.2340/actadv.v101.307
M3 - Article
C2 - 34618162
AN - SCOPUS:85121955765
SN - 0001-5555
VL - 101
JO - Acta dermato-venereologica
JF - Acta dermato-venereologica
IS - 11
M1 - adv00585
ER -